Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Somatropin + folic acid is a combination therapy being investigated by Beni-Suef University for the treatment of infertility in women with poor ovarian reserve (POR) undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Somatropin, a recombinant human growth hormone, is hypothesized to enhance ovarian response and oocyte quality by stimulating the production of insulin-like growth factor 1 (IGF-1) and modulating gonadotropin action. Folic acid is included as a standard prenatal supplement to support DNA synthesis and prevent neural tube defects. This specific combination is being evaluated in clinical trials to determine if growth hormone supplementation can improve the number and size of follicles and overall pregnancy outcomes in patients who typically respond poorly to standard ovarian stimulation protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on somatropin + folic acid.